Healthcare AI

About…

The company began in 2011 with a license from Duke and funding from Microsoft for small molecule drug discovery with AI. In collaboration with University of Florida, GSK, and others, we engaged in more than one dozen AI drug discovery programs. During the COVID-19 pandemic, Cloud spun out its small molecule discovery team into a quantum computing venture called PolarisQB and pivoted to GenAI for its next mission. PolarisQB continues to provide discovery services to Cloud.

Cloud Pharmaceuticals is a leader in artificial intelligence-based drug discovery. Cloud partners, designs, develops, and licenses novel drug compounds for a wide range of underserved medical indications to the pharmaceutical, biotechnology and medical research markets. With a mantra of ‘AI everywhere”, we are a multi-asset, multi-stage biotechnology company with a large, heavily partnered, risk diversified drug development pipeline. We are focused on making extensive use of artificial intelligence and computational modeling to choose, discover, and develop novel therapies to transform the lives of patients for a wide range of indications. The comprehensive application of AI to both our scientific development and the management of our risk diversified pipeline dramatically transforms the cost, speed and success rate of drug development and predictably yields a high return.
© 2020-4 Cloud All Rights Reserved